MYL12B Recombinant Monoclonal Antibody

MYL12B, also known as myosin regulatory light chain 12B or MLC-2, plays a fundamental role in regulating the actin-myosin contractile apparatus across multiple tissue types. This regulatory light chain modulates myosin ATPase activity through phosphorylation-dependent mechanisms, making it essential for processes ranging from smooth muscle contraction to non-muscle cell motility, cytokinesis, and cytoskeletal reorganization. Understanding MYL12B expression and localization provides valuable insights into cellular mechanics, cancer cell migration, and muscle physiology.

This recombinant monoclonal antibody, clone 10H1, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures that every lot performs identically to the last, eliminating the variability that can compromise longitudinal studies or multi-site collaborations. The rabbit IgG format, raised against a synthesized peptide from human MYL12B, has been affinity-purified to deliver high specificity for your target.

Validation studies demonstrate robust performance across multiple platforms. Immunohistochemistry testing in paraffin-embedded human skeletal muscle tissue confirms detection of MYL12B in its expected physiological context, while staining in human colorectal cancer tissue opens possibilities for investigating MYL12B's role in tumor cell motility and invasion. Flow cytometry validation using 786-O renal carcinoma cells shows clear positive signal separation from isotype controls, confirming utility for quantitative single-cell analysis of intracellular MYL12B levels.

This antibody serves researchers investigating cytoskeletal dynamics, muscle biology, cell migration mechanisms, and cancer metastasis. The validated compatibility with both tissue-based and cell-based applications provides flexibility for comprehensive experimental approaches examining MYL12B function and expression patterns.